Heilongjiang ZBD Pharmaceutical Co Ltd (603567) — Capital Reinvestment Ratio

Latest as of September 2025: 0.08x

Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥283.54 Million) in capital expenditures (CN¥21.27 Million). See 603567 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.08x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥283.54 Million
CNY

Capital Expenditures

CN¥21.27 Million
CNY

Data as of

Sep 2025
Most recent filing

Heilongjiang ZBD Pharmaceutical Co Ltd Capital Reinvestment Ratio (2011–2024)

This chart tracks Heilongjiang ZBD Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Check Heilongjiang ZBD Pharmaceutical Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)

Year-by-year Capital Reinvestment Ratio for Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024. For live market cap and broader valuation context, see how much is Heilongjiang ZBD Pharmaceutical Co Ltd worth.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 1.15x CN¥164.31 Million CN¥189.15 Million ▼ -79.4%
2020 5.60x CN¥155.18 Million CN¥868.65 Million ▲ +591.7%
2019 0.81x CN¥220.92 Million CN¥178.79 Million ▼ -29.1%
2018 1.14x CN¥367.40 Million CN¥419.59 Million ▲ +97.9%
2017 0.58x CN¥853.19 Million CN¥492.42 Million ▼ -97.1%
2016 20.14x CN¥15.83 Million CN¥318.74 Million ▲ +9644.1%
2014 0.21x CN¥386.32 Million CN¥79.85 Million ▼ -78.6%
2013 0.97x CN¥174.68 Million CN¥168.73 Million ▼ -36.1%
2012 1.51x CN¥154.25 Million CN¥233.09 Million ▲ +13.2%
2011 1.33x CN¥104.71 Million CN¥139.77 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow